<DOC>
	<DOCNO>NCT01437020</DOCNO>
	<brief_summary>Background : - Visceral leishmaniasis ( VL ) infection cause parasite carry sand fly . The parasite cause fever , weight loss , enlargement spleen liver . They also affect blood immune system . One possible treatment VL involve experimental drug call SCH708980 , may help prevent immune system become suppress worsen VL . Researchers want give drug along AmBisome ( Registered Trademark ) , kill parasite , see safe effective treatment . Objectives : - To study safety effectiveness SCH708980 , alone combine AmBisome ( Registered Trademark ) , treatment visceral leishmaniasis . Eligibility : - Individuals 18 60 year diagnose visceral leishmaniasis past 4 5 day , HIV-negative , willing stay hospital 30 day . - All participant come treat Kala-Azar Medical Research Center Muzaffarpur , India . Design : - This two-part study . Participants assign one part study . - Participants screen medical history physical exam ; blood , urine , stool sample , spleen bone marrow sample ; spleen measurement ; chest xray ; heart function test . - Part 1 participant separate two group : large group select dose study drug follow AmBisome 7 day later , small group placebo treatment follow AmBisome . - Part 2 participant either study drug placebo plus AmBisome , base test result Part 1 participant . - All participant monitor hospital 30 day , follow test : - Regular blood sample - Urine stool sample ( day 14 ) - Spleen measurement ( day 8 , 14 , 21 , 30 ) - Spleen bone marrow sample ( day 30 ) . Participants still VL symptom give another sample day 45 . - At 6 month start treatment , participant follow-up visit spleen measurement , blood stool sample , possible spleen bone marrow sample</brief_summary>
	<brief_title>SCH708980 With Without AmBisome Visceral Leishmaniasis</brief_title>
	<detailed_description>Visceral leishmaniasis ( VL ) kala-azar severe form leishmaniasis , fatal leave untreated . The majority VL case find resource-poor region , include India ( Bihar ) , Bangladesh , Brazil , Nepal , Sudan . VL pathogenesis link overproduction anti-inflammatory cytokine , interleukin ( IL ) -10 , promote parasite replication disease progression . Experimental model show IL-10 play key role pathogenesis VL . The current study two part . Part 1 open-label , dose-escalating design determine safety tolerability SCH708980 use combination AmBisome ( Registered Trademark ) . Part 2 randomize , single-blind , placebo-controlled , parallel design . A total 50 subject ( n=10 subjects/group ) enrol part 1 study . A group 10 subject observe 7 day prior receive AmBisome ( Registered Trademark ) ( 10 mg/kg ) 8th day , part control group . Subsequently , 40 subject ( 10 subjects/group ) receive single intravenous ( IV ) infusion SCH708980 ( 0.3 mg/kg , 1.0 mg/kg , 3.0 mg/kg , 10 mg/kg ) follow single IV infusion AmBisome ( Registered Trademark ) ( 10 mg/kg ) 7 day later . The first 2 subject dose group receive SCH708980 follow 3 day drug administer treatment initiate remain 8 subject group . Also , individual group follow 7 day AmBisome ( Registered Trademark ) administer next high dose-level group enrol study . Dose escalation continue next dose level unless dose-limiting toxicity occur &gt; 20 % subject cohort . The dose level SCH708980 use part 2 study decide 30 day start AmBisome ( Registered Trademark ) treatment group receive high dose part 1 . Randomization accrual part 2 study begin time . The high safe dose SCH709890 ( &lt; 20 % subject dose-limiting toxicity ) administer subject , exceed 10 mg/kg . Thirty subject ( n=10 subjects/group ) randomize 1:1:1 receive : 1 . A single IV infusion SCH708980 ( less equal 10.0 mg/kg ) day 1 follow single IV infusion AmBisome ( Registered Trademark ) ( 3.75 mg/kg ) day 8 . 2 . A single IV infusion SCH708980 ( less equal 10.0 mg/kg ) day 1 follow single IV infusion AmBisome ( Registered Trademark ) ( 5 mg/kg ) day 8 . 3 . A single dose placebo day 1 follow single IV infusion AmBisome ( Registered Trademark ) ( 10 mg/kg ) day 8 . SCH709890 placebo administer 60 minute , AmBisome ( Registered Trademark ) administer 120 minute .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects ( 18 60 year age ) meet follow criterion eligible enter study : Newly diagnose VL ( within 4 5 day screen ) confirm spleen bone marrow aspirate . Clinical sign symptom compatible VL : fever ( &gt; 99 degree F ) 2week duration , splenomegaly ( palpable spleen costal margin ) , weight loss . Biochemical hematological test value : Hemoglobin &gt; 6.0g/100mL . WBC count &gt; 1.0 time 10 ( 9 ) /L . Platelet count &gt; 40 time 10 ( 9 ) /L . Aspartate aminotransferase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase &lt; 3 time upper limit normal . Prothrombin time ( PT ) &lt; 4 second control value . Serum creatinine level within normal limit ( male , 0.7 mg/dL 1.1 mg/dL ; female , 0.6 mg/dL 0.9 mg/dL ) . Human immunodeficiency virus ( HIV ) negative status . Willingness hospitalize 30 day . Willingness sample store . Negative serum pregnancy test result woman childbearing potential . EXCLUSION CRITERIA : A history intercurrent concurrent disease ( e.g. , chronic alcohol consumption drug addiction ; renal , hepatic , cardiovascular , central nervous system disease ; diabetes ; tuberculosis infectious major psychiatric disease ) may introduce variable affect outcome study . Any condition , investigator 's opinion , may prevent subject complete study subsequent followup . Previous treatment VL within 45 day study enrollment . A history allergy hypersensitivity amphotericin B . Prior treatment failure amphotericin B . Current use drug know antileishmanial activity ( e.g. , antimonials , pentamidine , paromomycin , miltefosine ) , azoles ( e.g. , fluconazole , ketoconazole itraconazole ) , nephrotoxic drug , immunosuppressive drug , investigational agent , immunomodulatory drug . Breastfeeding woman Vaccinations within 30 day prior enrollment study . Exclusion child : Subjects young 18 year age exclude study insufficient data available support dose SCH708980 adult judge potential risk child . Exclusion woman : Pregnant lactate woman exclude study insufficient data available support dose SCH708980 population judge potential risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>IL-10</keyword>
	<keyword>Leishmaniasis</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>